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Abstract
Importance—The use of a non-mydriatic camera for retinal imaging combined with the remote 
evaluation of images at a telemedicine reading center has been advanced as a strategy for diabetic 
retinopathy (DR) screening, particularly among patients with diabetes from minority populations 
with low eye care utilization.
Objective—To examine the rate and types of DR identified through a telemedicine screening 
program using a non-mydriatic camera, as well as the rate of other ocular findings.
Design—Cross-sectional.
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Setting—Four urban clinic or pharmacy settings in the United States serving predominantly 
minority and uninsured persons with diabetes.
Participants—Persons age ≥ 18 years old who have type 1 or 2 diabetes and present to the 
community-based settings.
Main Outcome Measure—Percentage of DR detection including type of DR, and percentage of 
detection of other ocular findings.
Results—A total of 1,894 persons participated in the screening program across sites, with 21.7% 
having DR in at least one eye. The most common type of DR by far was background DR, which 
was present in 94.1% of all participants with DR. Almost half of those screened had ocular 
findings other than DR with 30% of other findings being cataract.
Conclusions and Relevance—In a DR telemedicine screening program in urban clinic/
pharmacy settings in the US serving predominantly minority populations, 1 in 5 persons with 
diabetes screened positive for DR. The vast majority of DR was background indicating high public 
health potential for intervention in DR’s earliest phases when treatment can prevent vision loss. 
Other ocular conditions were detected at a high rate, a collateral benefit of DR screening programs 
that may be under appreciated.
There are approximately 29.1 million persons with diabetes in the United States,1 with the 
prevalence expected to increase dramatically in future decades.2 A common diabetes 
complication is diabetic retinopathy (DR),1 whose prevalence is expected to increase.3 
Approximately 4.4% of Americans over 40 years old have DR.4 The personal and economic 
burdens of DR are noteworthy. DR is the leading cause of new blindness among working-
age adults in the US,1 with an estimated economic burden of $493 million per year.5 
Prevention and optimal management of DR consists of tight glycemic and blood pressure 
control, routine dilated comprehensive eye examination, timely treatment, and patient 
education.6-8 The American Academy of Ophthalmology (AAO), American Optometric 
Association, and American Diabetes Association recommend routine, annual dilated 
examination for persons with diabetes -- for type 1 diabetes, beginning 5 years after 
diagnosis, and for type 2, at the time of diagnosis and annually thereafter.9-11 The 
percentage of Americans with diabetes annually receiving dilated eye care is low. Data 
analysis of the Behavioral Risk Factor Surveillance System revealed a dilated examination 
annual rate of 63.3% in persons with self-reported diabetes.12 Among minority populations 
with diabetes, the annual eye exam rate is even lower, approximately 32-49% among 
African Americans and Hispanics.13-16 Common barriers to care for minority populations 
are lack of accessibility (scarcity of providers in communities; transportation challenges) 
and cost.17-21
The implementation of DR screening programs is associated with an increase in the 
percentage of people with diabetes receiving retinal screenings, a lower rate of those with 
sight-threatening DR detected at subsequent screenings, and a lower incidence and 
prevalence of blindness in the population.22-25 The use of a non-mydriatic camera for retinal 
imaging combined with the remote evaluation of images at a telemedicine reading center has 
been advanced as a strategy for DR screening and is used widely in national screening 
programs.26-30 Studies show that DR screening results using non-mydriatic cameras via 
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telemedicine agree with gold-standard dilated fundus photography.31-33 This screening 
strategy may be particularly relevant for people with diabetes who face barriers due to 
transportation and cost in seeking comprehensive dilated eye care from an ophthalmologist 
or optometrist.34,35 Screenings are brief compared to dilated examination, less burdensome 
since dilation is not required, and take place in the primary care setting or in novel settings 
such as pharmacies. Patients express satisfaction with this screening approach.36-38 Clinic 
personnel can be trained to operate the camera and upload images to a reading center.33,39 
There is growing evidence that DR screening programs, combined with telemedicine, are 
cost-effective interventions.25,40,41
Here we seek to examine the feasibility and effectiveness of non-invasive DR screening 
using a non-mydriatic camera combined with a telemedicine reading center. We focus on 
screening settings accessible to patients with diabetes in four cities in the United States, 
namely primary care clinics and pharmacies providing services to largely uninsured and/or 
minority populations.
Methods
This study was approved by the Institutional Review Boards of Johns Hopkins University 
(JHU), University of Alabama at Birmingham (UAB), University of Miami (UM), Wake 
Forest University, and Wills Eye Hospital (WEH), and followed the tenants of the 
Declaration of Helsinki. The protocol has been described in detail previously;42 our focus 
here is on the rates of DR and other ocular findings identified through the screening. Of the 
four study sites, three were based in outpatient clinics serving uninsured or underinsured 
populations with high representation of persons from ethnic/racial minorities. A fourth site 
was an outpatient pharmacy setting in an urban environment. Persons ages ≥ 18 years old 
who had been diagnosed with diabetes (Type 1 or 2) were invited to participate in a DR 
screening. Site-specific information is: (1) Birmingham, Alabama (UAB site): The Cooper 
Green Mercy Health Service’s internal medicine clinic is a county-operated, safety-net clinic 
serving county residents regardless of ability to pay or insurance status. English-speaking 
patients with diabetes were invited to participate from January to July 2012. (2) Miami, 
Florida (UM site): The Jessie Trice Community Health Center is a federally-qualified health 
center serving the uninsured or underinsured in the county. Participants were recruited via 
flyers and by referral from local physicians. Participants spoke English, Spanish, or Creole. 
Screening was from February 2012 to March 2013. (3) Winston-Salem, North Carolina 
(JHU site): The Downtown Health Plaza (DHP), affiliated with Wake Forest School of 
Medicine, serves low-income persons residing in the downtown area. Physicians and staff 
invited English-speaking individuals with diabetes to participate in screening, which was 
from May to October 2013. (4) Philadelphia, Pennsylvania (WEH site): The outpatient 
pharmacy at Thomas Jefferson University Hospital is located in an urban environment. 
English or Spanish speaking persons with diabetes were invited for screening by pharmacy 
personnel when picking up medications for diabetes, family practice physicians in nearby 
offices, flyers, or advertisements in newspapers. The screening program took place from 
December 2011 to March 2013. Participants provided informed consent.
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Participants completed a questionnaire providing contact information, demographics, age 
when first told by a physician that they had diabetes, whether they knew their hemoglobin 
A1c level, when they had their most recent dilated eye examination, smoking status, and 
health insurance status. They were asked if they needed assistance in making an eye 
appointment once their DR screening results were available.
Ocular imaging was performed by trained technicians using a non-mydriatic camera with 
auto-focus (Model AFC-230, Nidek Inc., Fremont, CA). Dark fabric was draped over the 
participant’s head and/or the room was darkened. Technicians were trained by the WEH 
telemedicine reading center in camera use and followed the manufacturer’s standard 
operating instructions. Three photos were taken per eye: anterior segment, nasal fundus, 
temporal fundus. If images were blurry, additional images were taken to achieve satisfactory 
image quality. Images were generated using NavisLite software (Nidek Inc, Fremont, CA) 
and uploaded to a HIPPA-compliant secure website at WEH.
Trained/certified readers at WEH read the images. A HIPPA-compliant proprietary software 
program was used for image management and report generation. Readers evaluated images 
using the National Health Service’s DR grading classification system (Table 1).43 Cataracts 
were graded according to a protocol using anterior segment photographs. Established 
algorithms were used to identify other ocular disease including hypertensive retinopathy, 
age-related macular degeneration, and glaucoma. As described previously,42 a 10% random 
sample of images labeled normal by the readers were reviewed by an ophthalmologist; none 
were found to have signs of pathology. The intra-rater kappa coefficient for readers with 
respect to DR findings was 0.72 with 88.8% agreement. The inter-grader kappa coefficient 
for DR findings was 0.62 (95% CI 0.51 – 0.73) with agreement of 84.1%. Readers assigned 
preliminary grades within 48 hours of image upload. Ocular pathology other than DR was 
recorded. A retina specialist reviewed images showing signs of DR or other ocular findings.
Results from the reading center’s review of images were summarized in a screening report 
sent electronically to the participant’s site. The coordinator mailed a letter to participants 
describing the results and recommended follow-up care based on the findings; the 
recommendations were derived from AAO’s guidelines for DR follow-up, based on the 
presence and degree of DR (Table 1).44 For participants whose reports recommended 
normal (non-urgent) referral or follow-up (R0, R1, P), the letter encouraged him/her to seek 
an appointment for a dilated eye examination on an annual basis. For abnormal results for 
R1 or P, the letter encouraged the participant to seek an appointment for a dilated eye 
examination “within the next few months”. For individuals whose reports recommended 
prompt referral to an eye care provider due to DR or maculopathy (R2, R3, M), the 
coordinator telephoned the participant within 48 hours of receiving the report from the 
reading center advising the participant of the recommendation and offered to schedule an 
appointment with an ophthalmologist. Up to 5 telephone attempts were made to reach 
participant. A letter was also mailed to the participant with results and recommendations. 
Patients with images deemed ungradable due to poor quality were advised to follow-up with 
an appointment for a dilated examination. Results were sent to the patient’s primary care 
provider if he/she had requested this
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Data Management and Statistical Analysis
Each site oversaw its own data entry and securely transmitted it to the data coordinating 
center at UAB, where a multi-site database was constructed and data analysis performed. 
Chi-square tests and analysis of variance was used to compare categorical and continuous 
variables, respectively, across groups. P-values of ≤0.05 (two-tailed) were considered 
statistically significant.
Results
A total of 1,894 persons participated in screening (Table 2), with 31.7% of the sample from 
Birmingham, 32.1% from Miami, 26.7% from Philadelphia and 9.5% from Winston-Salem. 
Mean age at each site was similar, ranging from 53 to 55 years old. There were more women 
(63.1%) than men (36.9%). The majority of those screened were ethnic/racial minorities 
(88%); however, there were site differences. In Birmingham most participants were African 
American (84.3%); in Philadelphia and Winston-Salem, approximately 68% of participants 
were African American with a larger percentage of whites than in Birmingham, whereas in 
Miami 63.6% were Hispanic, Haitian or Cuban American and 33.9% African American, 
with very few whites screened.
Mean age of diabetes diagnosis by self-report was in the 40s (Table 2). Mean duration of 
diabetes was approximately 8-10 years in Birmingham, Miami, and Philadelphia, but longer 
(14.6 years) in Winston-Salem. Approximately 25% of the sample reported smoking or 
using tobacco. The percentage of patients with health insurance was wide ranging, from 
22.6% at Miami to 79.2% in Philadelphia. There was site variability for when participants 
reported receiving their last dilated eye examination. About half of Birmingham participants 
reported having a dilated eye examination within the past year, yet at other sites, those 
reporting eye care utilization within the past year ranged from 25.5–32.4%. At Miami 
almost half (45.0%) reported receiving a dilated examination 2 or more years ago and 11.2% 
reporting never having a dilated examination. Approximately 30–42% of participants at 
Miami, Philadelphia, and Winston-Salem indicated they knew their A1C level, but only 
13.5% in Birmingham.
Across the sample, 21.7% of participants had DR (background, pre-proliferative, 
proliferative, and/or maculopathy) in either eye; by site, Birmingham 23.5%, Miami 24.1%, 
Philadelphia 15.8% and Winston-Salem 24.3%. Figure 1 shows the percentage of 
participants with specific types of DR in either eye. At Birmingham, Miami, and Winston-
Salem, background DR was present in 22-23% of participants, but lower in Philadelphia 
(14%). Among patients with DR, the vast majority had background DR (94.1%), with rates 
of pre-proliferative and proliferative DR ranging from 0-11.4% depending on the site. The 
proportion of participants with maculopathy in the overall sample was 9.3%. The rate of 
maculopathy was similar in Birmingham, Miami, and Winston-Salem, ranging from 9-11%, 
but was approximately half that rate in Philadelphia (5.4%). Depending upon the site, no or 
very few participants displayed evidence of having had photocoagulation treatment. Twelve 
percent had at least one ungradable image in one or both eyes.
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The prevalence of DR (regardless of type) was similar for whites versus ethnic/racial 
minority groups taken together (22.6% vs. 21.6%, p = 0.739), and was unrelated to time 
since dilated eye examination (p = 0.438), smoking/tobacco use (p = 0.400), health 
insurance status (p = 0.211), or knowledge of hemoglobin A1C level (p = 0.819). Those 
with DR had a longer duration of diabetes than those without DR (mean 13.7 years (SD 9.8) 
vs. mean 8.8 (SD 10.4), p < 0.0001).
Almost half of participants (44.2%) had ocular findings besides DR, with variability across 
sites. Miami had double the prevalence of other ocular findings (61.1%) compared to 
Birmingham (29.7%), with Philadelphia and Winston-Salem between the two extremes. 
Table 3 lists the percentage of other ocular findings in either eye by type in the overall 
sample. The most common other finding was cataract, present in almost ⅓ of participants. 
Hypertensive retinopathy, followed by glaucomatous/optic nerve findings, cotton wool spots 
and age-related macular degeneration were also noted. Pterygium notations were much less 
common, and nevus was rare. Figure 2 displays types of other ocular findings stratified by 
site.
Discussion
One in five patients with diabetes screened positive for DR using a telemedicine screening 
program in four urban settings in the US serving predominantly minority populations. This 
rate is similar to that reported in two previous US studies also using telemedicine reading 
centers.45,46 Three of our sites, based at primary care clinics, had very similar rates of DR, 
23-24%, but the Philadelphia site (a pharmacy) was lower (15.8%), which could result from 
many factors. Patients who fill prescriptions may be more medically adherent and less likely 
to have diabetes complications.47,48 Philadelphia had a higher percentage with health 
insurance (79.2%) as compared to other sites (34.6%). Patients with diabetes having health 
insurance are more likely to have better glycemic control and lower rates of diabetic eye 
disease compared to those lacking health insurance.16,49,50 Given the lower DR rate in the 
pharmacy cohort, it may be that screening in this setting will have lower yield than in 
outpatient clinics, an issue for further study.
The majority (94.1%) of persons with DR had background DR, which is similar to screening 
programs in primary care settings in the US and Canada.28,29,34,36,45,46 Patients with 
proliferative disease were rare at all sites. From a public health perspective, our finding that 
most patients with DR had background DR, with almost 10% of persons with diabetes 
screened having maculopathy, indicates high potential for intervention in DR’s earliest 
phases when treatment can prevent vision loss. In contrast to a United Kingdom report,51 the 
rate of DR detected in our program was not higher among ethnic/racial minorities compared 
to whites of European origin. At first glance this may seem paradoxical since the prevalence 
of DR among African Americans and Hispanics in the US is higher than in whites of 
European descent.52,53 Only 12% of participants were white; this small sample size may 
have made it difficult to evaluate white versus racial/ethnic minority differences in our 
screening program.
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DR was unrelated to smoking status, health insurance status, and knowledge of one’s 
hemoglobin. These findings highlight the potential benefit of a DR screening program for 
the general population of people with diabetes, rather than a more narrow approach for only 
a selected subpopulation. However, DR was more likely in persons with longer durations of 
diabetes, a well-established risk factor. This finding underscores the importance for 
screening programs to target those with long-standing diabetes.
The rate of self-reported dilated eye care utilization in the past year was low for the overall 
sample (32.2%), suggesting that DR screening in these settings could fulfill a critical role for 
patients with diabetes not routinely accessing annual dilated care. There were interesting 
differences across sites in the reported dilated examination rates. In Birmingham over half 
(52.8%) reported having a dilated examination within the past year, whereas at the other 
sites dilated examination rate was considerably lower (25-32%). Unlike the other sites, 
Birmingham’s county-operated health system has an ophthalmology clinic. The other 
primary care sites did not have onsite eye services. This may have contributed to a higher 
eye care utilization rate among Birmingham patients, since care was accessible onsite.54 The 
situation was inverted in Miami where almost half (45%) of those screened reported not 
having a dilated eye examination in ≥ 2 years, with 11.2% reporting never having one. 
Previously the clinic had an on-site optometrist which was closed prior to study start. It 
remains to be determined whether these factors influenced the lower rate of eye care 
utilization.
Almost half of participants had other ocular findings. This is an important collateral benefit 
of DR screening programs since many ocular findings detected are potentially sight-
threatening conditions (e.g., cataract, glaucoma, macular degeneration) yet are amenable to 
vision-preserving treatments. The most common other ocular finding was cataract. 
Glaucomatous/optic nerve findings were the most commonly noted conditions in 
Birmingham, not surprising given the high percentage of Blacks in the sample (84.3%), who 
have 4-5 times greater risk for glaucoma-associated disorders as compared to whites.55,56 
Pterygium occurred in over 10% of persons screened in Miami but was rare at other sites, 
which may reflect the higher risk of pterygium for persons residing closer to the equator or 
with prolonged ultraviolet light exposure.57,58
The rate of other ocular findings differed substantially among sites. Miami had the highest 
other ocular finding rate at over 60%. In contrast, Birmingham had half the rate (~30%). 
While DR screening has the additional benefit of identifying other potentially sight 
threatening conditions, the particular lesion types and their frequency in the population 
screened depends on demographics, lifestyle, and utilization of comprehensive eye services.
Study strengths include a focus on evaluating a DR screening program in urban settings that 
predominantly serve patients with diabetes from racial/ethnic minorities and uninsured or 
underinsured populations, an approach receiving only scant attention previously.59,60 Our 
target populations have among the lowest comprehensive eye care utilization rates in the 
US, thus being at high risk for undetected DR. Screening incorporated a non-mydriatic 
camera that is rapid and less burdensome and a central reading center through telemedicine. 
Multiple sites allowed us to implement the program in diverse geographic locations. Study 
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limitations include selection bias during enrollment; it is unknown whether those who 
participated versus did not were systemically different. Information is unavailable on the 
percentage of persons who declined participation. Although inclusion of four different sites 
enhances generalizability, sites differed in many ways; factors contributing to site 
differences cannot be precisely determined, yet can be addressed in future research. One site 
had fewer participants than the others because of delayed start-up. Although here we have 
not focused on patient follow-up for recommended eye appointments, acuity screening, and 
patient satisfaction, these issues will be addressed in subsequent reports.
In a DR telemedicine screening program in urban clinic and pharmacy settings in the US 
serving predominantly minority populations, 1 in 5 persons with diabetes screened positive 
for DR. Most had background DR, suggesting high potential for intervention in DR’s 
earliest phases when management can prevent vision loss. Other ocular conditions were 
detected in almost 50% of patients screened, a potentially under-appreciated feature of DR 
screening programs for preventing vision loss.
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Figure 1. 
Percentage of sample with various levels of diabetic retinopathy in either eye stratified by 
site and overall
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Figure 2. 
Percentage of the sample having other ocular findings in either eye stratified by site.
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Table 1
Classifications used to grade Diabetic Retinopathy (DR) presence and severity based on the National Health 
Service Grading Classification System.43 The last column is the American Academy of Ophthalmology’s 
recommendations for diabetic patient follow-up.44
Grade Description Recommendation
R0 NO DIABETIC RETINOPATHY Re-evaluate in twelve
months with either eye care
specialist or photographic
screening
None
Isolated cotton wools spots (1 or more) in the absence of any
microaneurysm or haemorrhage
R1 BACKGROUND DR Refer to eye care provider
1 or more microaneurysm(s)
1 or more retinal haemorrhage(s)
Any exudates caused by DR
R2 PRE-PROLIFERATIVE DR Refer to ophthalmologist
promptly
Intraretinal microvascular abnormality (IRMA)
Venous beading
Venous loop or reduplication
Multiple deep, round or blot haemorrhages
R3 PROLIFERATIVE DR Refer to ophthalmologist
promptly
New vessels on the disc (NVD)
New vessels elsewhere (NVE)
Pre-retinal or vitreous hemorrhage
Pre-retinal fibrosis with or without tractional retinal detachment due
to DR
M MACULOPATHY Refer to ophthalmologist
promptly
Exudate within 1 disc diameter (DD) of the center of the fovea
Circinate or group of exudates within the macula
Any microaneurysm or haemorrhage within 1 DD of the center of the
fovea only if associated with a best visual acuity of 20/40 or worse
P PHOTOCOAGULATION Refer to eye care provider
Focal/grid to macula
Peripheral scatter
U UNCLASSIFIABLE/UNGRADABLE Refer to eye care provider
Due to poor photographic location, focus, or contrast
JAMA Ophthalmol. Author manuscript; available in PMC 2016 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Owsley et al. Page 15
Table 2
Other characteristics of sample stratified by site and overall
Characteristic Birmingham
AL
N = 600
Miami FL
N = 608
Philadelphia
PA
N = 506
Winston-
Salem NC
N = 180
Total
N = 1894
Age (years), M (SD) 53.6 (10.6) 55.2 (9.1) 53.8 (10.6) 55.7 (13.0) 54.4 (11.0)
Gender, n (%)
 Women 393 (65.5) 398 (65.6) 282 (56.2) 118 (66.3) 1191 (63.1)
 Men 207 (34.5) 209 (34.4) 220 (43.8) 60 (33.7) 696 (36.6)
Race/ethnicity, n (%)
 Black 506 (84.3) 206 (33.9) 345 (68.2) 124 (68.9) 1181 (62.4)
 Hispanic 2 (0.3) 250 (41.1) 14 (2.8) 15 (8.3) 281 (14.8)
 White 87 (14.5) 8 (1.3) 95 (18.8) 38 (21.1) 228 (12.0)
 Haitian 0 (0) 70 (11.5) 0 (0) 0 (0) 71 (3.7)
 Cuban 0 (0) 67 (11.0) 1 (0.2) 0 (0) 68 (3.6)
 Asian 3 (0.5) 2 (0.3) 23 (4.6) 0 (0) 28 (1.5)
 Native Hawaiian 0 (0) 0 (0) 0 (0) 1 (0.6) 1 (< 0.1)
 Native American 0 (0) 0 (0) 0 (0) 1 (0.6) 1 (< 0.1)
 Other1 2 (0.3) 5 (0.8) 27 (5.3) 1 (0.6) 35 (1.8)
Age (years), M (SD) 53.6 (10.6) 55.2 (9.1) 53.8 (10.6) 55.7 (13.0) 54.4 (11.0)
Age at diabetes diagnosis,
years, M (SD) 43.9 (12.6) 46.6 (11.1) 44.0 (15.7) 41.2 (14.6) 44.5 (13.3)
Duration of diabetes, years,
M (SD) 9.7 (9.4) 8.6 (8.2) 9.9 (12.5) 14.6 (13.5) 9.9 (10.5)
Currently smokes2, n (%) 172 (28.7) 88 (14.5) 109 (21.6) 61 (34.1) 430 (22.8)
Knows A1C level 81 (13.5) 184 (30.5) 207 (42.4) 58 (32.4) 530 (28.3)
Has any type of health
insurance, n (%) 177 (29.5) 136 (22.6) 370 (79.2) 92 (51.7) 775 (42.0)
Last dilated eye
examination, n (%)
 Within past year 317 (52.8) 155 (25.5) 163 (32.4) 48 (27.0) 683 (32.2)
 > 1 year ago but < 2
years ago 85 (14.2) 111 (18.3) 116 (23.1) 38 (21.4) 350 (18.5)
 ≥ 2 years 153 (25.5) 273 (45.0) 168 (33.4) 62 (34.8) 656 (34.7)
 Never 23 (3.8) 68 (11.2) 37 (7.4) 14 (7.9) 142 (7.5)
 Don’t know 22 (3.7) 0 (0) 19 (3.8) 16 (9.0) 57 (3.0)
M = mean, SD = standard deviation
1
Multi-racial or no data available
2
Refers to smoking cigarettes, pipes, cigars or any tobacco use
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Table 3
Number and percentage of patients with other ocular findings
Type of Other Ocular Findings Total n = 1894
n (%)
Cataract 581 (30.7)
Hypertensive retinopathy 316 (16.7)
Cotton wool spots 211 (11.1)
Glaucomatous or optic nerve findings 197 (10.4)
Age-related macular degeneration (AMD) 174 (9.2)
Pterygium 90 (4.8)
Nevus 11 (0.6)
Miscellaneous1 101 (5.3)
1Other ocular findings classified as miscellaneous are those that were noted on the screening reports in ≤ 5 participants at all sites. These included 
retinal scar, epiretinal membrane, myelinated nerve fibers, vitreous opacity, asteroid hyalosis, corneal findings, embolic material, glia, macular 
hole, choroidal folds, peripapillary atrophy, vein or artery occlusion, iris findings, melanocytoma, horizontal folds, retinal striae, and posterior 
vitreous detachment
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